cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Mohammad Rizki Fadhil Pratama
Contact Email
mohammadrizkifadhilpratama@umpr.ac.id
Phone
+6287815093560
Journal Mail Official
bjop@umpr.ac.id
Editorial Address
Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya Building B 1st Floor, RTA Milono St. Km.1,5. Palangka Raya 73111, INDONESIA
Location
Kota palangkaraya,
Kalimantan tengah
INDONESIA
Borneo Journal of Pharmacy
Published by Universitas Muhammadiyah Palangkaraya
ISSN : -     EISSN : 26214814     DOI : https://doi.org/10.33084/bjop
Core Subject : Health,
Medicine & Pharmacology
Borneo Journal of Pharmacy publishes various scientific articles covering Pharmacy and Pharmaceutical Sciences in the field but not limited to: Pharmacology-Toxicology, including pharmacokinetics, pharmacodynamics, pharmacotherapy, and toxicology. Pharmacognosy-Phytochemistry, including pharmacognosy, phytochemistry, ethnobotany, and ethnopharmacology. Pharmaceuticals, including biopharmaceuticals, pharmaceutical technology, formulations, and biotechnology. Analytical Pharmacy-Medicinal Chemistry, including pharmaceutical chemistry, chemical analysis, medicinal chemistry, bioinformatics, pharmacy physics, pharmaceutical analysis, and method validation. Microbiology Pharmacy, including the antibacterial, antifungal, and antiviral activity test. Natural Product Development, including testing the pharmacological activity of extracts, fractions, and plant isolates. Clinical-Community Pharmacy, including monitoring usage, side effects, counseling, and drug use evaluation. Management Pharmacy, including drug management, drug use profiles, pharmaceutical administration, and marketing.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 300 Documents
 24   25   26   27   28 
Formulation and Evaluation of Soursop (Annona muricata) Leaf Extract Nanoemulgel Against Propionibacterium acnes Ikramina, Nabila; Rehana, Rehana; Prasetya, Rahmad Aji; Kurniawan, Dhadhang Wahyu
Borneo Journal of Pharmacy Vol. 7 No. 4 (2024): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v7i4.5977

Abstract

Annona muricata (soursop) leaves are rich in antimicrobial compounds such as flavonoids, alkaloids, tannins, saponins, and phenols. This study aimed to develop a nanoemulgel formulation incorporating A. muricata leaf ethanol extract to enhance its efficacy against Propionibacterium acnes, a bacterium associated with acne vulgaris. Four nanoemulgel formulations containing varying concentrations of the extract (0%, 0.5%, 0.7%, and 1%) were prepared and evaluated for their physical properties (organoleptic, homogeneity, pH, spreadability, and viscosity) and stability through freeze-thaw cycles. The formulation with the highest extract concentration (Formula III) was selected for further characterization (particle size, morphology, and zeta potential) and antimicrobial testing against P. acnes. All formulations met the established physical property and stability criteria. Formula III exhibited a particle size of 20.5 nm and a zeta potential of 9.8 mV, indicating a stable nanoemulsion with well-dispersed particles. Antimicrobial testing revealed that Formula III demonstrated a strong inhibitory effect against P. acnes, with an average inhibition zone of 19.00 mm. These findings suggest that A. muricata leaf extract-loaded nanoemulgel has the potential to be a promising topical formulation for acne treatment. Further research is warranted to optimize the formulation and evaluate its efficacy in clinical settings.
Physicochemical Properties and Antioxidant Potential of Gels from Foam Mat Drying and Ethanolic Extract of Red Spinach (Amaranthus cruentus) Arifin, Ibrahim; Anwar, Khoirul; Arsyada, Muhammad Farih; Pratiwi, Nevy; Shabrina, Ayu
Borneo Journal of Pharmacy Vol. 7 No. 4 (2024): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v7i4.6162

Abstract

Red spinach (Amaranthus cruentus), a rich source of antioxidant anthocyanins, is susceptible to light degradation. Foam mat drying (FMD) is a promising technique to preserve these pigments. This study compared the physicochemical properties and antioxidant activity of gels incorporating FMD and ethanolic extracts of A. cruentus (EEAC). Both were incorporated into gels at varying concentrations (1%, 3%, and 5%). FMD gels exhibited a darker red color and significantly higher total anthocyanin content (8.33 ± 0.25/100 g) and stronger antioxidant activity (IC50 of 35.67 ± 1.87 ppm) compared to EEAC gels (10.45 ± 0.15/100 g and IC50 of 47.88 ± 2.45 ppm, respectively). Both gel types had similar pH values (5.32-5.77). Increasing the concentration of either extract affected the viscosity, spreadability, and adhesion of the gels. Importantly, FMD gels displayed significantly higher antioxidant activity (58.75 ± 2.12 to 64.72 ± 2.01%) than EEAC gels (31.75 ± 2.13 to 50.12 ± 3.01%) across all formulations. These findings suggest that FMD-based gels offer a superior delivery system for A. cruentus antioxidants, potentially leading to innovative food products with enhanced nutritional value and health benefits.
Monoclonal Antibodies for Treatment of COVID-19: An Updated Review of Current Evidence Nimesh, Saurabh; Kumari, Pratibha; Kumar, Rohit; Gosiya, Gosiya; Quamuddin, Md.; Ahmad, Md. Iftekhar
Borneo Journal of Pharmacy Vol. 7 No. 4 (2024): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v7i4.6365

Abstract

The emergence of COVID-19 in December 2019 spurred a global effort to develop effective medical interventions. Therapeutic monoclonal antibodies (mAbs) have emerged as a promising strategy to combat the SARS-CoV-2 virus. Several mAbs targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein have received Emergency Use Authorization (EUA) for treating mild to moderate COVID-19. Additionally, human mAbs and hyperimmune plasma derived from recovered COVID-19 patients have been explored as potential therapeutic options. This review delves into the potential of mAbs for the diagnosis and treatment of COVID-19 infection. We discuss the mechanisms of action of mAbs, as well as their advantages and limitations. Furthermore, we explore the ongoing research and development efforts to optimize mAb-based therapies for COVID-19.
Polyphenol Content and Antioxidant Evaluation of Kawista (Limonia acidissima) Leaf Extract Fawwaz, Muammar; Pratama, Mamat; Razak, Rais; Andika, Yusrianti; Astika, Elvina; Feralia, Feralia
Borneo Journal of Pharmacy Vol. 7 No. 4 (2024): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v7i4.7466

Abstract

Kawista or Limonia acidissima, a plant traditionally used by the Bima community, offers potential health benefits. This study aimed to evaluate the antioxidant potential of ethanol extract from L. acidissima leaves by determining total flavonoid content (TFC), total phenolic content (TPC), and antioxidant activity using DPPH, FRAP, and CUPRAC assays. The ethanol extract exhibited significant antioxidant activity, with IC50 values of 10.445 and 135.42 µg/mL for DPPH and CUPRAC assays, respectively. TPC and TFC were determined to be 14.63 mgGAE/g extract and 113.9 mgQE/g extract, respectively. These findings suggest that L. acidissima leaf extract possesses potent antioxidant properties, which may be attributed to its flavonoid and phenolic content. Further research is warranted to explore this plant extract's underlying mechanisms of action and potential therapeutic applications.
Post-COVID Mucormycosis: An Emerging Threat in Developing Countries - A Prospective Review Chakraborty, Debpratim; Adhikary, Sudipa
Borneo Journal of Pharmacy Vol. 7 No. 4 (2024): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v7i4.7690

Abstract

COVID-19, with its rapidly mutating strains, poses a significant global health challenge. Recent reports of a surge in mucormycosis cases among COVID-19 patients highlight the urgent need for understanding and addressing this critical complication. This review explores the factors contributing to mucormycosis development in COVID-19 patients and outlines strategies for prevention and management. Several factors, including high glucose levels (diabetes, onset, steroid-induced hyperglycemia), low oxygen levels, elevated iron levels (especially ferritin), metabolic acidosis, and diabetic ketoacidosis, can facilitate the germination of mucor spores. COVID-19 patients with underlying conditions such as diabetes, cancer, or organ transplants are particularly susceptible to mucormycosis due to their immunocompromised state. The growth of the mucor pathogen requires free iron, which is elevated in conditions like diabetic ketoacidosis. This elevated iron level promotes the formation of Cot-H, a crucial component of fungal growth, leading to mucormycosis. Additionally, comorbidities and corticosteroids can suppress the immune system, hindering the body's ability to fight off infections like mucormycosis. Therefore, it is imperative to avoid the indiscriminate use of corticosteroids. Strict control of acute hyperglycemia and comprehensive monitoring of diabetic and immunocompromised COVID-19 patients are essential preventive measures. By addressing these factors, healthcare providers can mitigate the risk of mucormycosis in COVID-19 patients and improve overall outcomes.
Cover, Content, and Editorial Note from Borneo J Pharm Vol. 7 No. 3 August 2024 Borneo J Pharm, Chief Editor of
Borneo Journal of Pharmacy Vol. 7 No. 3 (2024): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v7i3.8442

Abstract

Assalamu’alaikum Wr. Wb. Alhamdulillahirabbil ‘alamin. The next edition of Borneo Journal of Pharmacy (Borneo J Pharm), has been published at August 2024. This edition contains ten articles: Pharmacology-Toxicology, Pharmacognosy-Phytochemistry, Analytical Pharmacy-Medicinal Chemistry, Microbiology Pharmacy, Natural Product Development, Clinical-Community Pharmacy, and Pharmaceutical Education. This edition includes writings from four countries: India, Indonesia, Italy, and Malaysia. The authors come from several institutions, including Universitas Muhammadiyah Malang, Universitas Ahmad Dahlan, Universitas Muhammadiyah Banjarmasin, Universitas Jember, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, University of Kalyani, Azienda Ospedaliero Universitaria Maggiore della Carita, Universitas Airlangga, Institut Ilmu Kesehatan Bhakti Wiyata Kediri, Universitas Islam Bandung, Universitas Mulawarman, Universitas Negeri Yogyakarta, Universitas Gadjah Mada, Universitas Kristen Duta Wacana, Universitas Global Jakarta, and Management and Science University. Editorial boards are fully aware that there are still room for improvement in this edition, hence with all humility willing to accept constructive suggestions and feedback for improvements to the publication for the next editions. The editorial board would like to thank all editors and reviewers, and contributors of the scientific articles who have provided the repetoire in this issue. We hope that all parties, especially the contributors, could re-participate for the publication in the next edition on November 2024. Wassalamu’alaikum Wr. Wb.
Cover, Content, and Editorial Note from Borneo J Pharm Vol. 7 No. 4 November 2024 Borneo J Pharm, Chief Editor of
Borneo Journal of Pharmacy Vol. 7 No. 4 (2024): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v7i4.9143

Abstract

Assalamu’alaikum Wr. Wb. Alhamdulillahirabbil ‘alamin. The next edition of the Borneo Journal of Pharmacy (Borneo J Pharm), has been published in November 2024. This edition contains ten articles: Pharmacology-Toxicology, Pharmacognosy-Phytochemistry, Pharmaceutical, Analytical Pharmacy-Medicinal Chemistry, Microbiology Pharmacy, Natural Product Development, and Clinical-Community Pharmacy. This edition includes writings from five countries: India, Indonesia, Saudi Arabia, Sudan, and Taiwan. The authors come from several institutions, including Institut Sains dan Teknologi Nasional, Taipei Medical University, Metro College of Health Sciences and Research, Galgotias University, Yogendra Nath Saxena College of Pharmacy and Research Centre, Shri Gopichand College of Pharmacy, Jadavpur University, Maulana Abul Kalam Azad University of Technology, Universitas Muslim Indonesia, Universitas Jenderal Soedirman, Akademi Farmasi Surabaya, University of Khartoum, National Medicines Quality Control Laboratory, Al Jouf University, Universitas Sari Mulia, Universitas Muhammadiyah Purwokerto, Universitas Muhammadiyah Kalimantan Timur, Universitas Muhammadiyah Palangkaraya, Universitas Wahid Hasyim, Universitas Jenderal Achmad Yani, and Ibrahim Adjie Primary Care. Editorial boards are fully aware that there is still room for improvement in this edition, hence with all humility willing to accept constructive suggestions and feedback for improvements to the publication for the next editions. The editorial board would like to thank all editors and reviewers, and contributors of the scientific articles who have provided the repertoire in this issue. We hope that all parties, especially the contributors, could re-participate for publication in the next edition in March 2025. Wassalamu’alaikum Wr. Wb.
Antioxidant Activity of Edible Bird’s Nest (Aerodramus fuciphagus) from Central Borneo, Indonesia Sandi, Dita Ayulia Dwi; Susiani, Eka Fitri; Rahmatullah, Satrio Wibowo; Adnyana, I Ketut; Wikaningtyas, Pratiwi
Borneo Journal of Pharmacy Vol. 8 No. 1 (2025): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v8i1.6595

Abstract

Edible bird's nests (EBNs) from Aerodramus fuciphagus have been traditionally used in Asia for their various health benefits, including antioxidant properties. Previous studies have reported antioxidant activity in EBN water extracts using methods like ABTS and ORAC. However, the antioxidant activity can vary significantly depending on factors such as the source of EBN, extraction methods, and the specific assay used. This study aimed to comprehensively evaluate the antioxidant potential of EBN water extract using a range of in vitro assays. The antioxidant activity was assessed using four different methods: 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging, nitric oxide (NO) radical scavenging, ferric reducing antioxidant power (FRAP), and cupric reducing antioxidant capacity (CUPRAC). Results demonstrated that the EBN water extract exhibited moderate NO radical scavenging activity with an IC50 value of 116.86 μg/mL. While weak activity was observed in the DPPH assay, the FRAP and CUPRAC assays showed promising antioxidant potential with an ascorbic acid equivalent (AAE) of 4.567±0.30 and 3.487±0.095 μg AAE/mL, respectively. These findings suggest that the antioxidant activity of EBN water extract may be primarily attributed to its protein content. However, further investigations are warranted to elucidate the specific mechanisms of action and isolate the bioactive compounds responsible for the observed antioxidant effects. These findings have implications for the development of EBN-based functional foods, nutraceuticals, and cosmeceuticals with enhanced antioxidant properties.
Potential of Moringa oleifera Effervescent Granules as a New Antacid: Micronutrients, Formulation, and Evaluation Mughrbi, Hanin Nafed; Elghnimi, Tamader Youssef; Aljawadi, Jumana
Borneo Journal of Pharmacy Vol. 8 No. 1 (2025): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v8i1.7793

Abstract

Moringa oleifera, a nutritionally rich plant widely distributed in tropical and subtropical regions, possesses a diverse array of medicinal properties. This study aimed to develop and evaluate effervescent granules from M. oleifera leaves and seeds, assessing their in vitro acid neutralization capacity (ANC) compared to a commercial antacid. Micronutrient content (calcium and magnesium) of both leaf and seed powders was quantified using flame photometry. Effervescent granules were formulated using wet granulation, and their physicochemical properties were evaluated. The ANC was determined in simulated gastric juice. Results revealed that M. oleifera leaves contained significantly higher calcium and magnesium levels than seeds. Two-way ANOVA demonstrated that both leaf and seed effervescent granules, at 5 and 10 g, exhibited significantly higher ANC than the negative control. Post-hoc Tukey's test further indicated that the leaf granules possessed superior ANC compared to seed granules, and equivalent efficacy to 5 g of the commercial antacid. These findings suggest that M. oleifera leaves and seeds can be effectively formulated into effervescent granules with potent antacid properties. The observed ANC, likely attributed to the high micronutrient content of the leaves, highlights a novel nutraceutical application for M. oleifera as a potential alternative to conventional antacids.
Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review Meriyani, Herleeyana; Sanjaya, Dwi Arymbhi; Juanita, Rr. Asih; Siada, Nyoman Budiartha; Chusna, Nurul; Ketupapa, Florentina Gabriela
Borneo Journal of Pharmacy Vol. 8 No. 1 (2025): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v8i1.7913

Abstract

Triple-negative breast cancer is an aggressive and poor prognosis subtype of breast cancer. Eribulin has shown promise in the treatment of metastatic triple-negative breast cancer (mTNBC). This review aimed to provide a specific description, evidence, and discussion of the efficacy and safety of eribulin both as monotherapy and in combination with another agent in patients with mTNBC. The search was conducted in five databases (PubMed, ScienceDirect, PLoS One, Wiley Online Library, and Cochrane Library) towards published articles during the 2013-2023 period. A total of 237 articles were identified. After removing 69 duplicates, 168 articles underwent the screening process and 10 articles met the research criteria. Eribulin monotherapy effectiveness profile includes: overall survival (10.8-17.6 months), progression-free survival (2.8-3.2 months), partial response (21.0%-58.7%), progressive disease (15.5% -47.0%), and stable disease (28.8%-32%). However, there were no cases of complete response. Combination of eribulin with other agents' effectiveness profiles includes: overall survival (8.3-14.5 months), PFS (2.6-8.1 months), partial response (31.8-76.0%), complete response (2.4-8%), progressive disease (8.0-28%), and stable disease (8.0-52.3%). Eribulin monotherapy's safety profile is similar to that of combination therapy. No grade 5 adverse event was reported during monotherapy or in combination with other agents. The grade 4 adverse events reported are neutropenia, leukopenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, vomiting, dyspnea, back pain, arthralgia, febrile neutropenia, dyspnea, constipation, general physical health deterioration, alopecia. The all-grade adverse events with a percentage above 50% are neutropenia, leukopenia, thrombocytopenia, asthenia, alopecia, elevated AST, elevated ALT, hand-foot syndrome, fatigue, anemia, peripheral neuropathy, oral mucositis, and nausea.

Page 26 of 30 | Total Record : 300

 24   25   26   27   28 

Filter by Year

2018 2025


Reset
Filter By Issues
All Issue Vol. 8 No. 4 (2025): Borneo Journal of Pharmacy Vol. 8 No. 3 (2025): Borneo Journal of Pharmacy Vol. 8 No. 2 (2025): Borneo Journal of Pharmacy Vol. 8 No. 1 (2025): Borneo Journal of Pharmacy Vol. 7 No. 4 (2024): Borneo Journal of Pharmacy Vol. 7 No. 3 (2024): Borneo Journal of Pharmacy Vol. 7 No. 2 (2024): Borneo Journal of Pharmacy Vol. 7 No. 1 (2024): Borneo Journal of Pharmacy Vol. 6 No. 4 (2023): Borneo Journal of Pharmacy Vol. 6 No. 3 (2023): Borneo Journal of Pharmacy Vol. 6 No. 2 (2023): Borneo Journal of Pharmacy Vol. 6 No. 1 (2023): Borneo Journal of Pharmacy Vol. 5 No. 4 (2022): Borneo Journal of Pharmacy Vol. 5 No. 3 (2022): Borneo Journal of Pharmacy Vol. 5 No. 2 (2022): Borneo Journal of Pharmacy Vol. 5 No. 1 (2022): Borneo Journal of Pharmacy Vol. 4 No. 4 (2021): Borneo Journal of Pharmacy Vol. 4 No. 3 (2021): Borneo Journal of Pharmacy Vol. 4 No. 2 (2021): Borneo Journal of Pharmacy Vol. 4 No. 1 (2021): Borneo Journal of Pharmacy Vol. 3 No. Special-1 (2020): Borneo Journal of Pharmacy: COVID-19 Vol. 3 No. 4 (2020): Borneo Journal of Pharmacy Vol. 3 No. 3 (2020): Borneo Journal of Pharmacy Vol. 3 No. 2 (2020): Borneo Journal of Pharmacy Vol. 3 No. 1 (2020): Borneo Journal of Pharmacy Vol. 2 No. 2 (2019): Borneo Journal of Pharmacy Vol. 2 No. 1 (2019): Borneo Journal of Pharmacy Vol. 1 No. 2 (2018): Borneo Journal of Pharmacy Vol. 1 No. 1 (2018): Borneo Journal of Pharmacy More Issue